stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Free cash flow
Xenon Pharmaceuticals Inc.'s free cash flow for fiscal 2025 was −$279.9M, compared with −$184.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$338.5M. Over the past ten years it has ranged from −$279.9M (fiscal 2025) to −$6.0M (fiscal 2019) — the current reading is the lowest in ten years. Free cash flow has fallen for 6 consecutive fiscal years. Xenon Pharmaceuticals Inc. ranks 573rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$279.9M | — |
| FY2024 | −$184.5M | — |
| FY2023 | −$156.7M | — |
| FY2022 | −$101.3M | — |
| FY2021 | −$71.6M | — |
| FY2020 | −$50.8M | — |
| FY2019 | −$6.0M | — |
| FY2018 | −$35.2M | — |
| FY2017 | −$29.0M | — |
| FY2016 | −$19.8M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$95.7M | — |
| Mar 2026 | −$89.0M | — |
| Dec 2025 | −$81.8M | — |
| Sep 2025 | −$72.0M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $82.0M |
| PBLS Parabilis Medicines, Inc. compare | −$119.1M |
| ABCL AbCellera Biologics Inc. compare | −$119.7M |
| TNGX Tango Therapeutics, Inc. compare | −$144.2M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$216.1M |
| XENE Xenon Pharmaceuticals Inc. | −$338.5M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement